肾肿块活检是否影响多学科治疗建议
本研究分析多学科团队将肾肿块活检(RMB)纳入决策后对治疗策略的影响。83例≤4 cm肿块患者中66%接受RMB,活检诊断率87%,9%的核心活检显示良性病理。活检组推荐主动监测的比例为34%,无活检组为64%;活检组推荐消融的比例为38%,无活检组为7%。
要点
- ≤4 cm肾肿块多学科讨论中,66%患者接受RMB,87%活检可诊断,9%核心活检为良性病理。
- 有活检数据者推荐主动监测34%、消融38%,无活检者分别为64%和7%。
- 活检后最终行部分肾切除术者组织学一致率93%,并发症率1.5%。
核心结论
- 超过半数SRM患者接受了RMB,85%的病例获得诊断;RMB通过提供肾肿块生物学信息辅助共享决策,有助于指导多学科管理及考虑保留肾单位方案。
研究设计与样本
- 多学科团队(放射介入操作者、病理学家和泌尿外科医生)每月召开肾肿块会议,结构化呈现患者人口学、合并症、肿瘤病理、实验室和影像学特征;活检方案标准化为在肾超声引导下使用带鞘装置的18G核心针活检;总结活检诊断率及与肾切除标本的一致性;采用描述性统计评估RMB对管理决策的影响。
诊断标准与关键数值
- 共讨论83例≤4 cm肿块患者,66%接受RMB;其中87%可诊断,9%的核心活检显示良性病理;活检队列中推荐主动监测34%、消融38%、部分肾切除术约17%,无活检队列分别为64%、7%、约22%;并发症率1.5%,仅1例Clavien-Dindo 2级并发症;活检后最终行部分肾切除术者组织学一致率93%。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose: To examine how a multidisciplinary team approach incorporating renal mass biopsy (RMB) into decision making changes the management strategy.Methods: A multidisciplinary team comprised of a radiology proceduralist, a pathologist and urologists convened monthly for renal mass conference with a structured presentation of patient demographics, co-mborbidities, tumor pathology, laboratory and radiographic features. Biopsy protocol was standardized to an 18-gauge core needle biopsy using a sheathed apparatus under renal ultrasound guidance. Biopsy diagnostic rate, and concordance with nephrectomy specimens were summarized. Descriptive statistics were used to evaluate influence of RMB on management decisions.Results: A total of 83 patients with a ≤4 cm mass were discussed, and 66% of patients underwent RMB. Of those, 87% were diagnostic with 9% of core biopsies showing benign pathology. Active surveillance (AS) was recommended for 34% of patients with biopsy data as compared to 64% of those without biopsy. Ablation was recommended for 38% of the biopsy cohort compared to 7% without biopsy. Partial nephrectomy rates were similar for both cohorts, approximately 17% and 22%, respectively. Our complication rate was 1.5%, with only 1 Clavien-Dindo Grade 2 complication. Histology was concordant in 93% of patients that ultimately underwent partial nephrectomy after biopsy.Conclusions: Over half of our SRM patients underwent a RMB that provided a diagnosis in 85% of cases. RMB aided in shared decision making by providing insight into the biology of renal masses, which helps to guide multidisciplinary management and consideration of nephron sparing options.
引用
- Lobo JM, Clements MB, Bitner DP, et al. Does renal mass biopsy influence multidisciplinary treatment recommendations? Scand J Urol. 2019. PMID: 31868063. doi:10.1080/21681805.2019.1703805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。